Sustained release intraocular drug delivery devices for treatment of uveitis

Journal of Ophthalmic and Vision Research

Volumn 6, Issue 4, 2011, Pages 317-319

  Haghjou, Nahid ^a   Soheilian, Masoud ^b   Abdekhodaie, Mohammad Jafar ^a  

^a SHARIF UNIVERSITY OF TECHNOLOGY   (Iran)

^b SHAHID BEHESHTI UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Corticosteroid; Drug delivery; Steroid sparing medications; Sustained release; Uveitis

Indexed keywords

EID: 84855599366     PISSN: 20082010     EISSN: 2008322X     Source Type: Journal    
DOI: None     Document Type: Review

References (51)

1. Jabs DA, Nussenblatt RB, Rosenbaum JT. Standardization of uveitis nomenclature for reporting clinical data. Results of the First International Workshop. Am J Ophthalmol 2005;140:509-516.
2. Rothova A, Suttorp-van Schulten MS, Frits Treffers W, Kijlstra A. Causes and frequency of blindness in patients with intraocular inflammatory disease. Br J Ophthalmol 1996;80:332-336.
3. Suttorp-Schulten MS, Rothova A. The possible impact of uveitis in blindness: a literature survey. Br J Ophthalmol 1996;80:844-848.
4. Haupert CL, Jaffe GJ. New and emerging treatments for patients with uveitis. Int Ophthalmol Clin 2000;40:205-220.
5. Helzner J. Sustained-Release Drugs: Heralds of the Future. Ophthalmology management March 2010.
6. Jaffe GJ, Martin D, Callanan D, Pearson PA, Levy B, Comstock T. Fluocinolone acetonide implant (Retisert) for noninfectious posterior uveitis: thirtyfour- week results of a multicenter randomized clinical study. Ophthalmology 2006;113:1020-1027.
7. Callanan DG, Jaffe GJ, Martin DF, Pearson PA, Comstock TL. Treatment of posterior uveitis with a fluocinolone acetonide implant: three-year clinical trial results. Arch Ophthalmol 2008;126:1191-1201.
8. Pavesio C, Zierhut M, Bairi K, Comstock TL, Usner DW; Fluocinolone Acetonide Study Group. Evaluation of an intravitreal fluocinolone acetonide implant versus standard systemic therapy in noninfectious posterior uveitis. Ophthalmology 2010;117:567-575.
9. Mohammad DA, Sweet BV, Elner SG. Retisert: is the new advance in treatment of uveitis a good one? Ann Pharmacother 2007;41:449-454.
10. Kane FE, Burdan J, Cutino A, Green KE. Iluvien (TM): a new sustained delivery technology for posterior eye disease. Expert Opinion on Drug Delivery 2008;5:1039-1046.
11. Lee SS, Yuan P, Robinson MR. Ocular implants for drug delivery. In: Wnek GE, Bowlin GL (eds). Encyclopedia of Biomaterials and Biomedical Engineering. 2nd ed. New York: Informa Healthcare, USA, Inc.; 2008: 2259-2269.
12. Seah SK, Husain R, Gazzard G, Lim MC, Hoh ST, Oen FT, et al. Use of Surodex in phacotrabeculectomy surgery. Am J Ophthalmol 2005;139:927-928.
13. Lee SY, Chee SP. Surodex after phacoemulsification. J Cataract Refract Surg 2005;31:1479-1480.
14. Tan DT, Chee SP, Lim L, Theng J, Van Ede M. Randomized clinical trial of Surodex steroid drug delivery system for cataract surgery: anterior versus posterior placement of two Surodex in the eye. Ophthalmology 2001;108:2172-2181.
15. Kodama M, Numaga J, Yoshida A, Kaburaki T, Oshika T, Fujino Y, et al. Effects of a new dexamethasone-delivery system (Surodex) on experimental intraocular inflammation models. Graefes Arch Clin Exp Ophthalmol 2003;241:927-933.
16. Allergan, Inc. Allergan receives FDA approval for Ozurdex™ biodegradable, injectable steroid implant with extended drug release for retinal disease. Press Release. Irvine, CA: Allergan; June 18, 2009. http://agn.client.shareholder.com/releasedetail.cfm?ReleaseID=390519. Accessed September 15, 2009.
17. Ozurdex. www.allergan.com/research_and_development/pipeline.htm. Accessed May 27, 2010.
18. Mansoor S, Kuppermann BD, Kenney MC. Intraocular sustained-release delivery systems for triamcinolone acetonide. Pharm Res 2009;26:770-784.
19. Kiss S. Sustained-release corticosteroid delivery systems. Retina Today 2010(June):44-46.
20. Ashton P, Brown JD, Pearson PA. Intravitreal ganciclovir pharmacokinetics in rabbits and man. J Ocular Pharmacol 1992;8:343-347.
21. Jaffe GJ, Pearson PA, Ashton P. Dexamethasone sustained drug delivery implant for the treatment of severe uveitis. Retina 2000;20:402-403.
22. Jaffe GJ, Ben-Nun J, Guo H, Dunn JP, Ashton P. Fluocinolone acetonide sustained drug delivery device to treat severe uveitis. Ophthalmology 2000;107:2024-2033.
23. Jaffe GJ, Yang CS, Wang XC, Cousins SW, Gallemore RP, Ashton P. Intravitreal sustained-release cyclosporine in the treatment of experimental uveitis. Ophthalmology 1998;105:46-56.
24. Manez R, Jain A, Marino IR. Comparative evaluation of tacrolimus (FK506) and cyclosporin A as immunosuppressive agents. Transpl Rev 1995;9:63-76.
25. BenEzra D, Maftzir G, deCourten C, Timonen P. Ocular penetration of cyclosporine A. III: The human eye. Br J Ophthalmol 1992; 76:350-352.
26. Walton RC, Nussenblatt RB, Whitcup SM. Cyclosporine therapy for severe sight-threatening uveitis in children and adolescents. Ophthalmology 1998;105:2028-2034.
27. Deray G, Benhmida M, Le Hoang P, Maksud P, Aupetit B, Baumelou A. Renal function and blood pressure in patients receiving long-term, low-dose cyclosporine therapy for idiopathic autoimmune uveitis. Ann Intern Med 1992;117:57-83.
28. Nussenblatt RB, Dinning WJ, Fujikawa LS, Chan CC, Palestine AG. Local cyclosporine therapy for experimental autoimmune uveitis in rats. Arch Ophthalmol 1985;103:1559-1562.
29. Pearson PA, Jaffe GJ, Martin DF, Cordahi GJ, Grossniklaus H, Schmeisser ET, et al. Evaluation of a delivery system providing long term release of cyclosporine. Arch Ophthalmol 1996;114:311-317.
30. Gilger BC, Malok GE, Stewart T, Horohov D, Ashton P, Smith T, et al. Effect of an intravitreal cyclosporine implant on experimental uveitis in horses. Vet Immunol Immunopathol 2000;76:239-255.
31. Dong X, Shi W, Yuan G, Xie L, Wang S, Lin P. Intravitreal implantation of the biodegradable cyclosporin a drug delivery system for experimental chronic uveitis. Graefes Arch Clin Exp Ophthalmol 2006;244:492-497.
32. Fung AE. A Novel Sustained-release Intravitreal Drug Delivery System for Retinal Vascular Disease. Retina Today 2010(April):51-53.
33. Fung AE. One-year safety and efficacy of an injectable, sustained-delivery, liquid steroid for treatment of macular edema due to retinal vein occlusion. Angiogenesis. Miami, Florida, USA. February 20, 2010.
34. Mainardes RM, Urban MC, Cinto PO, Khalil NM, Chaud MV, Evangelista RC, et al. Colloidal carriers for ophthalmic drug delivery. Curr Drug Targets 2005;6:363-371.
35. De Kozak Y, Andrieux K, Villarroya H, Klein C, Thillaye-Goldenberg B, Naud MC, et al. Intraocular injection of tamoxifen-loaded nanoparticles: a new treatment of experimental autoimmune uveoretinitis. Eur J Immunol 2004;34:3702-3712.
36. Nagarwal RC, Kant S, Singh PN, Maiti P, Pandit JK. Polymeric nanoparticulate system: A potential approach for ocular drug delivery. J Controlled Release 2009;136:2-13.
37. Herrero-Vanrell R, Refojo MF. Biodegradable microspheres for vitreoretinal drug delivery. Adv Drug Deliv Rev 2001; 52:5-16.
38. Kwak HW, D'Amico DJ. Evaluation of the retinal toxicity and pharmacokinetics of dexamethasone sodium phosphate after intravitreal injection. Arch Ophthalmol 1992;110:259-266.
39. Gaudana R, Jwala J, Boddu SH, Mitra AK. Recent perspectives in ocular drug delivery. Pharm Res 2009;26:1197-1216.
40. Ashton P. Retinal Drug Delivery. In: Jaffe GJ, Ashton P, Pearson PA. (eds). Intraocular Drug Delivery. New York: Taylor & Francis Group; 2006: 6-7.
41. Lajavardi L, Bochot A, Camelo S, Goldenberg B, Naud MC, Behar-Cohen F, et al. Downregulation of endotoxin-induced uveitis by intravitreal injection of vasoactive intestinal peptide encapsulated in liposomes. Invest Ophthalmol Vis Sci 2007;48:3230-3238.
42. Camelo S, Lajavardi L, Bochot A, Goldenberg B, Naud MC, Brunel N, et al. Protective effect of intravitreal injection of vasoactive intestinal peptideloaded liposomes on experimental autoimmune uveoretinitis. J Ocul Pharmacol Ther 2009;25:9-21.
43. Lajavardi L, Camelo S, Agnely F, Luo W, Goldenberg B, Naud MC, et al. New formulation of vasoactive intestinal peptide using liposomes in hyaluronic acid gel for uveitis. J Control Release 2009;139:22-30.
44. Del Amo EM, Urtti A. Current and future ophthalmic drug delivery systems. A shift to the posterior segment. Drug Discov Today 2008;13:135-143.
45. Eljarrat-Binstock E, Pe'er J, Domb AJ. New Techniques for Drug. Delivery to the Posterior Eye Segment. Pharmaceutical Research 2010;27:4:530-543.
46. Myles ME, Loutsch JM, Higaki S, and Hill JM. Ocular Iontophoresis. In: Mitra AK (ed). Ophthalmic Drug Delivery Systems. 2nd ed. New York: Marcel Dekker Inc.; 2003: 365-408.
47. Lachaud JP. Considerations on the use of corticosteroids by ionization in certain ocular diseases. Bull Soc Ophthalmol Fr 1965;65:84-89.
48. Lam TT, Edward DP, Zhu XA, Tso MO. Transscleral iontophoresis of dexamethasone. Arch Ophthalmol 1989;107:1368-1371.
49. Eljarrat-Binstock E, Raiskup F, Frucht-Pery J, Domb AJ. Transcorneal and transscleral iontophoresis of dexamethasone phosphate using drug loaded hydrogel. J Control Release 2005;106:386-390.
50. Behar-Cohen FF, Parel JM, Pouliquen Y, Thillaye- Goldenberg B, Goureau O, Heydolph S, et al. Iontophoresis of dexamethasone in the treatment of endotoxin-induced-uveitis in rats. Exp Eye Res 1997;65:533-545.
51. Hastings MS, Li SK, Miller DJ, Bernstein PS, Mufson D. Visulex: advancing iontophoresis for effective noninvasive backto-the-eye therapeutics. Drug Delivery Tech 2004;4:53-57.